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Abstract 
Background 
We aimed to quantify contributions of changes in risks and uptake of evidence-based treatment 
to coronary heart disease (CHD) mortality trends in Japan between 1980 and 2012. 
Methods  
We conducted a modelling study for the general population of Japan aged 35 to 84 years using 
the validated IMPACT model incorporating data sources like Vital Statistics. The main outcome 
was difference in the number of observed and expected CHD deaths in 2012. 
Results 
From 1980 to 2012, age-adjusted CHD mortality rates in Japan fell by 61%, resulting in 75,700 
fewer CHD deaths in 2012 than if the age and sex-specific mortality rates had remained 
unchanged. Approximately 56% (95% uncertainty interval [UI]: 54–59%) of the CHD mortality 
decrease, corresponding to 42,300 (40,900–44,700) fewer CHD deaths, was attributable to 
medical and surgical treatments. Approximately 35% (28–41%) of the mortality fall 
corresponding to 26,300 (21,200–31,000) fewer CHD deaths, was attributable to risk factor 
changes in the population, 24% (20–29%) corresponding to 18,400 (15,100–21,900) fewer and 
11% (8–14%) corresponding to 8,400 (60,500–10,600) fewer from decreased systolic blood 
pressure (8.87 mmHg) and smoking prevalence (14.0%). However, increased levels of 
cholesterol (0.28 mmol/L), body mass index (BMI) (0.68 kg/m
2
), and diabetes prevalence 
(1.6%) attenuated the decrease in mortality by 2% (1–3%), 3% (2–3%), and 4% (1–6%), 
respectively. 
Conclusions 
Japan should continue their control policies for blood pressure and tobacco, and build a strategy 
to control BMI, diabetes, and cholesterol levels to prevent further CHD deaths. 
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Introduction 
Japan has the lowest coronary heart disease (CHD) mortality rate in the world 
1
. Death rates 
from acute myocardial infarction further declined in Japan from the 1980s to 2000s. 
Additionally, the relative decline in death rates from acute myocardial infarction was larger in 
Japan than in other Western populations 
2–4
. The decline in age-adjusted CHD mortality in 
Japan has occurred in spite of recent increases in key risk factors including elevated levels of 
body mass index (BMI) and cholesterol 
5–7
; however, that has occurred accompanied with a 
decrease of total cholesterol in other developed countries 
7
. Due to this uniqueness related to 
CHD mortality and its trend in Japan, strategies preventing further CHD deaths in Japan could 
be different from other developed countries. Therefore, it is important to quantify contributions 
of changes in risk factor levels towards changes in CHD mortality rates to identify effective 
strategies for preventing further CHD deaths in Japan. 
The IMPACT model was developed to explain the decline in CHD deaths by 
quantifying the contributions of temporal changes in exposure to risk factors and uptake of 
treatments. The model has been previously validated and used to help explain such falls in 
mortality in more than 20 countries 
8–13
. However, to our knowledge, no studies have attempted 
to quantify the relative contributions of specific therapies and risk factors in Japan, which has a 
population with low risk of CHD mortality. 
We, therefore, applied the IMPACT model to estimate the contribution of changes in 
risk factor levels and uptake of evidence-based treatment on trends in CHD deaths between 
1980 and 2012 in Japan. 
 
Methods 
We implemented the previously validated, cell-based, IMPACT mortality model for the 
Japanese adult population 
11
. The model was used to estimate the contributions of 
population-level risk factor changes and increases in the uptake of evidence-based treatments 
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on the CHD mortality decline in Japan between 1980 and 2012 for adults aged 35 to 84 years.  
The IMPACT mortality model applies the relative risk reduction quantified in previous 
randomised controlled trials (RCT) and meta-analyses to estimate the mortality reduction 
attributable to A) temporal change in risk factor prevalence and B) net change over the period in 
the uptake of specific treatments in patients with each specific form of CHD.  
The model includes all the major CHD risk factors: smoking, systolic blood pressure 
(SBP), total cholesterol, BMI, diabetes, and physical inactivity. It also includes the 16 
evidence-based medical and surgical treatments that are widely used in nine different disease 
groups 
11
. The present study was approved by the ethical committee of the National Cerebral 
and Cardiovascular Center in Suita, Japan (M27-104-2). 
 
Data  
We investigated all possible sources in Japan providing data to inform model parameters and 
selected the most up-to-date, representative datasets. We obtained mortality rates specific to 
age-sex groups for coronary heart disease from Vital Statistics in Japan 
(http://www.mhlw.go.jp/english/database/db-hw/vs01.html). Population estimates and CHD 
death counts ICD 9 (International classification of diseases, ninth revision codes 410-414, 429.2 
for 1980 and ICD 10 I20-I25 for 2012) by ten-year age-bands and sex were also obtained from 
Vital Statistics in Japan. 
 Data on admissions and medical treatments came from the Japanese Registry of All 
Cardiac and Vascular Diseases (JROAD) registry of the Japanese Circulation Society 
14
, 
National Patient Survey of Ministry of Health, Labour and Welfare 
15
, and the All-Japan-Utstein 
Registry 
16
. Data on trends in risk factors came from the National Survey on Circulatory 
Disorders in 1980 and the National Health and Nutrition Survey (NHNS) in 2012 
17
. More 
details on data sources are available in the Technical Appendix (see Appendix 5.3).  
Diabetes prevalence in 1980 was defined as a casual blood sugar >200 mg/dl or treated 
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diabetes. However, we were unable to obtain diabetes prevalence in 2012 based on the same 
definition because casual blood sugar levels were not measured in 2012. Note that HbA1c 
levels were not measured in 1980. Therefore, we calculated the diabetes prevalence in 2012 as 
follows to use similar definitions between 1980 and 2012. First, we calculated the prevalence of 
diabetes based on HbA1c (≥6.5%) in 2012. Second, we calculated ratios of prevalence of 
diabetes based on casual blood sugar to that based on HbA1c in 2010. The ratios were 0.88 for 
men and 0.78 for women. Finally, the prevalence of diabetes calculated in the first step were 
multiplied by the ratio calculated in the second step. More details on this adjustment are 
provided in the Technical Appendix.  
 
Observed and expected number of CHD deaths 
Substantial changes in the coding of causes of death in Japan from ICD 9 to ICD 10 were 
introduced in 1995. Therefore, to estimate the true decline in the observed number of deaths 
from coronary heart disease in Japan for 1980-2012, official vital statics data needed to be 
adjusted. We estimated the number of deaths from coronary heart disease before 1995 by using 
a Poisson regression model, fitting the number of deaths from coronary heart disease as the 
outcome and years as the explanatory variable. A detailed explanation of these calculations is 
available in section 2.1 of the Technical Appendix.  
 The number of CHD deaths expected in 2012 was calculated by multiplying the age 
and sex-specific CHD mortality in 1980 by the relevant population counts for 2012, yielding 
the expected number of deaths in 2012 had age and sex-specific mortality rates remained 
unchanged since 1980. The difference between the number of expected and observed deaths 
represented the mortality fall, expressed as the total number of CHD deaths prevented or 
postponed (DPPs). This needed to be explained by the combined changes in risk factor levels 
and treatment uptake between 1980 and 2012. If the model did not fully explain all deaths 
prevented, we assumed any shortfalls would reflect unmeasured risk factors or imprecision in 
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the model parameters. 
 
Mortality reductions attributable to treatment uptake 
We specified relevant treatments for each of the nine mutually exclusive disease groups (see 
Technical Appendix). The first component of the IMPACT mortality model calculates the net 
benefit of treatments in 2012. Firstly, we calculated the estimated number of DPPs in 2012 by 
multiplying the 2012 age-sex- specific treatments uptake levels by the population counts for 
2012 in that age-sex-stratum, by the one-year case fatality rate and by the relative reduction in 
the case fatality rate estimated to be due to the administered treatment.  
Many effective treatments were not in use in 1980 in Japan. We therefore calculated 
the net benefit of treatments in 2012 as the difference between the number of untreated patients 
in 1980 and the number of patients treated in 2012 (i.e. using the 2012 uptake rates).  
We specified nine mutually exclusive disease groups (see Technical Appendix). To avoid double 
counting of patients, we constructed distinct, non-overlapping CHD patient subgroups. The 
patient numbers in some groups, for instance angina in community and heart failure in 
community, were therefore adjusted for several conditions. For example, we adjusted the 
number of angina patients in community to account for the fact that Japan has a large 
prevalence of vasospastic angina, estimated to be at 40% of angina cases 
18
. We also adjusted 
the number of heart failure patients in the community to allow for probable underestimation in 
the Patient Survey conducted by the Ministry of Health, Labour and Welfare, Japan. Details of 
these assumptions are presented in the Appendix, section 5.1. 
 
Mortality reductions attributable to risk factor changes 
We calculated the absolute change in each risk factor between 1980 and 2012 by using 
generalized linear models with normal distribution and identity link for the continuous risk 
factors (such as total blood cholesterol and BMI) and generalized linear models with a binomial 
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distribution and logit link function for categorical variables (for the details, please see Technical 
Appendix 2.1.). We then estimated the mortality benefits of an absolute change in each risk 
factor between 1980 and 2012 with a regression-based approach for factors measured on a 
continuous scale, using sex and age-specific independent regression coefficients of mortality 
benefit for a unit change in mean risk factor obtained from published multivariate analyses 
(Technical Appendix, table I). For binary variables (such as smoking), we used a population 
attributable risk fraction approach using sex and age-specific relative risks from the most recent 
meta-analyses and population cohort studies (Technical Appendix, Table J). 
Recent reductions in CHD mortality obviously reflect the result of simultaneous 
changes in multiple risk factors. We therefore jointly estimated mortality benefits of changes in 
risk factors by using the cumulative risk reduction approach, rather than simple addition 
(Technical Appendix, section 1.3). 
 
Sensitivity analysis 
We calculated 95% uncertainty intervals (UI) around the model output by using the Monte 
Carlo simulation. This calculation involved replacing all fixed input parameters used in the 
model by appropriate probability distributions and by repeatedly recalculating the model output 
with values sampled from the defined input distributions. We used the Excel add-in Ersatz 
software (www.epigear.com) to do 1000 runs to determine the 95% UIs of the deaths prevented 
or postponed (2.5th and 97.5th percentile values corresponding to the lower and upper limits) 
(see Technical Appendix). 
 
Results 
The number of CHD deaths in 2012 observed and expected (based on an assumption that CHD 
age and sex-specific mortality rates in 1980 persisted through 2012) were 49,300 and 125,000 
respectively. Thus, a total of 75,700 deaths were prevented or postponed (DPPs) (Table 1). 
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Of the 75,700 DPPs, approximately 42,300 ([UI]: 40,900–44,700) fewer CHD deaths 
were attributable to medical and surgical treatments representing some 56% (95% UI: 54% to 
59%) of the total mortality fall (Table 2 and Supplemental Figure 1). Approximately 26,300 
(21,200–31,000) fewer CHD deaths were attributable to risk factor changes in the population, 
representing some 35% (28% to 41%) (Table 2 and Supplemental Figure 1). The remaining 9% 
was attributed to changes in other unmeasured factors or model imprecision. 
 
Medical and Surgical Treatments 
Substantial contributions came from therapy for angina in the community (21.1% [20.5% to 
21.8%]) of the total mortality decrease corresponding to 16,000 [15,500 to 16,500] fewer CHD 
deaths) and for heart failure in the hospital (7.2% [6.4% to 8.1%] of the total mortality decrease 
corresponding to 5,500 [4,800 to 6,100] fewer CHD deaths)(Table 3 and Supplemental Figure 
1). ACE inhibitor and beta-blocker benefits across all diseases accounted for approximately 
12% (corresponding to 9,100 fewer CHD deaths) and 13% (corresponding to 9,800 fewer CHD 
deaths) respectively of the total mortality fall. Both had been introduced after1980. For the 
details, please see Table 3. 
 
Risk factor changes 
We observed both favourable and un-favourable risk factor changes. The largest contribution 
from risk factor changes at population level was due to the 8.4 mmHg fall in SBP in people not 
on antihypertensive drugs; this generated approximately 18,400 (14,900 to 22,300) fewer deaths, 
representing 24.4% (19.7% to 29.4%) of the total mortality decrease (Table 2). In contrast, the 
additional benefits from the treatment of SBP were three-fold less, and approximately 7,200 
(5,800 to 8,600) deaths averted corresponding to 9.5% (7.7% to 11.4%) of the total mortality 
decrease (Table 3). The second largest contribution came from the fall in population smoking 
rates, accounting for approximately 8,400 (5,900 to 10,600) deaths averted, corresponding to 
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11.1% (7.8% to 14.0%) of the total fall. Increased leisure time physical activity accounted for 
approximately 5,700 (4,500 to 6,700) deaths prevented or postponed corresponding to 7.5% 
(5.9% to 8.9%) of the total mortality decrease. 
The gains from decreases in SBP, smoking, and physical activity, were partly cancelled 
out by increases in cholesterol, BMI, and diabetes. Diabetes prevalence increased from 9% to 
11%, which resulted in approximately 2,600 (900 to 4,500) additional deaths, representing 
some 3.5% (1.2% to 5.9%) of the total deaths (Table 2). Increases in mean BMI from 22.5 in 
1980 to 23.2 in 2012 contributed approximately 2,000 (1,600 to 2,400) extra deaths, an 
additional 2.7% (2.1% to 3.2%) of total CHD deaths (Table 2). Increases in mean cholesterol 
(4.93 to 5.22 mmol/L) accounted for approximately 1,600 (760 to 2,600) additional deaths 
corresponding to 2.2% (1.0% to 3.4%) of the total CHD deaths (Table 2). This effect was 
blunted by subtraction of statin benefits (4.0% [3.4% to 4.6%] corresponding to 3,000 [2,600 to 
3,500] fewer CHD deaths)(Table 3). The contribution of all risk factors and treatments and their 
uncertainty are presented in Supplemental Figure 1. 
 
Discussion  
Principal findings 
Between 1980 and 2012, the age-adjusted CHD mortality rates in Japan decreased by 61%, 
resulting in 75,700 fewer CHD deaths. The IMPACT Japan model explained approximately 
91% of this mortality fall. Changes in medical treatments accounted for 56% (95% UI: 54% to 
59%) of the mortality decrease. Additionally, favourable risk-factor changes accounted for 
approximately 35% (28% to 41%), in spite of adverse trends in cholesterol, BMI, and diabetes.  
 
Relation to previous studies 
Medical and surgical treatments 
Cardiology treatments developed rapidly during the period of study in Japan (1980–2012). The 
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fewer CHD deaths in Japan were attributable to medical and surgical treatments representing 
56% (95% UI: 54% to 59%) of the total mortality fall, which was higher than that of the UK 
(42%) 
11
 and the US (47%) 
8
. This could be due to differences in healthcare systems. Japan has 
utilized universal health coverage that charges fees per service similar to the UK but could be 
less restrictive; however, the US did not have a similar system 
19
. On the other hand, results 
from the IMPACT model in Portugal show that approximately 50% of the CHD mortality 
reduction was due to changes in medical treatments, similar to our present results 
13
. Possible 
reasons for this similarity can be that both Japan and Portugal had lower age-standardized CHD 
mortality and had also utilized universal health coverage 
13,19
. 
Improvements in chronic angina management in Japan represented 21.1% (20.5% to 
21.8%) of the mortality reduction, similar to Canada 
9
. Community-based treatments for 
hypertension (9.5% [7.7% to 11.4%]), heart failure (7.2% [6.4% to 8.1%]), and statins (4.0% 
[3.4% to 4.6%]), also played major roles, similar to the US, the UK, Canada, and Sweden 
8,9,11,12,20
.  
Furthermore, the contribution of those treatments to the decline of CHD deaths is 
likely explained by the Japanese universal health coverage by which most people can obtain 
health services without suffering financial hardship 
19
. However, room for improvement still 
exists from ACE/ARBs treatment for AMI as follows. Twelve percent of the mortality reduction 
could be attributed to ACE/ARBs treatment that is expensive compared to cheaper alternatives, 
but freely affordable under the Japanese universal health coverage 
19
. The 3.8% (3.6% to 4.7%) 
of DPPs explained by AMI treatments in Japan was lower than the UK (7.7%) and the US 
(6.3%) 
8,11
, while 2.8% (2.6% to 2.9%) explained by unstable angina treatments which fell in 
the UK (1.5%) and the US (4.0%) 
8,11
. In Japan, beta-blockers and ACE/ARB for AMI have not 
been prescribed frequently, especially in small hospitals; the use of both treatments might 
further increase. 
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Major cardiovascular risk factors 
Net changes in major cardiovascular risk factors explained approximately 35% (28% to 41%) 
of the CHD mortality fall between 1980 and 2012. Some 24.4% (19.7% to 29.4%) was 
explained by decreased population blood pressure, even more than the US and Canada, both of 
which had around 20%
8,9
; this likely reflects the dramatic decrease in salt reduction attributable 
to public health interventions and westernised dietary patterns 
21,22,23
. Smoking prevalence in 
Japan declined from 35% (1980) to 21% (2012) and prevented approximately 8,400 (5,900 to 
10,600) fewer CHD deaths, some 11.1% (7.8% to 14.0%) of the total mortality fall, similar to 
Canada (9.5%) 
9
 and Sweden (9.1% in the entire population, 6.8% in the population without 
CHD for the primary prevention of CHD, and 6.9% in CHD patients for the secondary 
prevention of CHD) 
12,24
 but lower than the UK (48.1% in the entire population, 83.0% in the 
population without CHD for the primary prevention of CHD, and 17.0% in the population with 
CHD for the secondary prevention of CHD) 
11
,
25
. 
Increases in BMI and diabetes mirrored trends elsewhere and generated 6.2% of 
additional deaths. Mean cholesterol at population level had fallen in almost all Western 
countries except for Japan where total cholesterol increased steadily from 4.93 to 5.22 mmol/L 
to reach U.S levels 
7,26
. This rise generated approximately 1,600 (760 to 2,600) additional CHD 
deaths, in spite of statin treatments. This cholesterol rise probably reflects a progressive 
Westernisation of the healthy traditional Japanese diet and consumption of sugar, animal 
product, total fats, and oil increased four-fold from 1965 to 2005 
27,28
. Consumption of meat, 
milk, and dairy products also rose, increasing the ratio of saturated fatty acids to total energy 
intake 
23
, while vegetable intake remained constant 
29
 (Figure 1 in Appendix II). National 
nutritional surveys showing lower intake of vegetable, fruit, and seafood in younger age-groups 
raise concern for future increases in CHD, as in other populations 
1,14,30
. 
 
Strengths and weaknesses of the present study, and unanswered questions and future work 
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Our study has several strengths. Firstly, this is the first study to use high quality, nationally 
representative datasets to quantify the factors driving coronary mortality trends in Japan. For 
example, all hospital cardiac arrest cases were captured through the All-Japan-Utstein Registry, 
which is already validated 
31,32
. Risk factor distribution was obtained through the national 
nutritional survey, which was based on the randomly sampled nationwide population
33
. Second, 
our validated IMPACT model can transparently integrate and simultaneously consider huge 
amounts of data from many sources. 
Our study also has limitations. We used a validated methodology to adjust for the 
different version of ICD coding and. However, we might still have overestimated mortality 
rates in the 1980s. Additionally, we were unable to perform sensitivity analyses to estimate the 
effect of change in ICD coding on our results by using data in 1995 or 1996 (the coding method 
was changed in 1995 in Japan) instead of data in 1980 because we did not have enough data in 
1995 and 1996 to perform the IMPACT model. Second, diabetes prevalence in 1980 was 
defined as a casual blood sugar >200 mg/dl or as treated diabetes, though diabetes prevalence in 
2012 was calculated by multiplying that which was based on HbA1c in 2012 by the ratios of 
diabetes prevalence in 2010 based on casual blood sugar to that based on HbA1c. For the 
details, please see the methods section. However, the relative change observed was compatible 
with other studies 
34,35
. Third, we might have overestimated angina in the community due to the 
high prevalence of vasospastic angina in Japanese populations. However, we explicitly adjusted 
for this peculiarity of angina epidemiology in Japan (see Appendix). Fourth, the elderly, aged 
85 and above, were not included in the model due to lack of data. Fifth, we optimistically 
assumed that treatment effectiveness in the population equalled the efficacy reported in 
randomised trials, likely overestimating treatment benefits. Sixth, the IMPACT model used 
CHD mortality as the endpoint, and did not consider CHD morbidity. Thus, the estimation of 
DPPs could be improved by considering the burden of CHD morbidity. Finally, our model 
could not explain the overall 9% decline in CHD mortality. This perhaps reflected imprecision 
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of the model, or omission of other risk factors, such as psychosocial stress, alcohol, or fish 
omega-3 fatty acid consumption. That may also reflect that our model omitted stroke deaths (as 
a potential competing risk), of which mortality and prevalence were higher in Japan than in 
European countries and the US. For example, there may have been several people who would 
have died from CHD if they had not died from stroke. Thus, the present results should be 
interpreted by considering these limitations. 
 
Public health implications  
Preventive approaches, particularly population-based policies, are consistently more effective 
than healthcare-based primary prevention 
36
. Current efforts to prevent cardiovascular disease in 
Japan are based on the national health check-up promotion programs (see Appendix). However, 
such individual-level interventions appear less effective and equitable than population-wide 
structural interventions. 
37,38
 Population level policy approaches should therefore be considered 
as a potentially powerful and likely cost-saving strategy. In Japan, actions on salt have been 
extremely effective. For example, recently, Japanese Hypertension Society conducted a 
campaign for reducing salt by many publications such as recipe books, and successfully 
changed labels of salt contents in processed foods that consumers could easily understand 
21,22
. 
However, no regulation currently exists for reducing trans-fatty acids in Japan, which would be 
an effective intervention 
39
. Tobacco control policy could also be strengthened, along with 
mandatory salt reformulation in processed foods and sugar-sweetened beverage taxation. 
Finally, these results can be cautiously generalized to other countries in the 
Asia-Pacific region, such as countries like South Korea that have a similar epidemiological 
profile where AMI incidences increase due to an aging society and westernisation of lifestyle, 
especially for diet 
40,41
.  
In conclusion, the declining trend in CHD deaths in Japan was explained by policies 
reducing blood pressure and smoking, and by considerable application of evidence-based 
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treatment for CHD. However, these successes have been partly offset by the increase in diabetes, 
BMI, and cholesterol levels. Additionally, effective population-based policy approaches may 
therefore now be required to reduce the future burden of CHD in Japan.
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Table 1. Population aged from 35 to 84, observed coronary heart disease deaths, age-standardized rates for 1980 and 2012, and deaths 
prevented or postponed (DPPs) in Japan. 
 Men and women Men Women 
Year 1980 2012 1980 2012 1980 2012 
Population 53,026,428 79,457,000 25,119,073 38,445,000 27,907,355 41,012,000 
Observed CHD deaths 41,572 49,273 31,226 32,838 18,102 16,435 
Age-standardized rate (per 100,000) † 78.4 37.5 96.2 54.1 62.2 22.5 
Expected deaths†† - 124,955 - 80,710 - 44,245 
DPPs‡ - 75,682 - 47,872 - 27,810 
% of expected deaths prevented - 60.60% - 59.30% - 62.90% 
†The direct method of age-standardized rates was used with the Japanese population aged 35-85 (ten-year age-bands) in 1980 as 
standard to calculate the age-standardized rates according to the aim of the present study. 
†† 
Expected deaths = the number of CHD deaths in 2012 was calculated on an assumption that age and sex-specific CHD mortality 
rates in 1980 continued through 2012. 
‡
DPPs = expected – observed deaths in 2012. 
Abbreviations: CHD, coronary heart disease; DPPs, deaths prevented or postponed.  
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Table 2. Coronary heart disease deaths prevented or postponed (DPPs) due to changes in total treatment, and changes in prevalence and 
levels of risk factors between 1980 and 2012 in Japan.  
 
DPPs  
(95% uncertainty interval*) 
% of total DPPs 
(95% uncertainty 
interval*) 
Total treatments and risk factors prevalence 75,682 NA 
Explained by changes in total treatments 42,336 (40,868 to 44,652)  56% (54% to 59%) 
Explained by changes in risk factor prevalence and risk factor levels 26,280 (21,191 to 31,030) 35% (28% to 41%) 
Systolic blood pressure† (decreased by 8.87 mmHg in the period) 18,445 (14,909 to 22,251) 24.4% (19.7% to 29.4%) 
Total cholesterol‡ (increased by 0.28 mmol/L in the period) -1,645 (-2,573 to -757) -2.2% (-3.4% to -1.0%) 
Body mass index
 
(increased by 0.68 kg/m
2
 in the period) -2,013 (-2,422 to -1,589) -2.7% (-3.2% to -2.1%) 
Smoking (decreased by 14.0% in the period) 8,407 (5,903 to 10,595) 11.1% (7.8% to 14.0%) 
Physical inactivity (decreased by 18.5% in the period) 5,714 (4,465 to 6,736) 7.5% (5.9% to 8.9%) 
Diabetes (increased by 1.6% in the period) -2,627 (-4,465 to -908) -3.5% (-5.9% to -1.2%) 
Unexplained by the present IMPACT model 7,065 9% (NA) 
Abbreviations: DPPs, deaths prevented or postponed. 
*95% uncertainty interval corresponds to 2.5th and 97.5th percentiles limits of uncertainty analysis.  
†After subtracting DPPs due to antihypertensives in primary prevention. 
‡After subtracting DPPs due to statin treatment in primary prevention. 
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Table 3. Coronary heart disease deaths prevented or postponed (DPPs) due to changes in specific 
treatment between 1980 and 2012 in Japan.  
Treatments by patient groups DPPs % of total DPPs 
 (95% uncertainty interval*) (95% uncertainty interval*) 
Total treatments  42,336 (40,868 to 44,652) 56% (54% to 59%) 
Acute myocardial infraction† 2,842 (2,725 to 3,557) 3.8% (3.6% to 4.7%) 
Aspirin 564 0.70% 
ACE inhibitors 131 0.20% 
Beta-blockers 61 0.10% 
CABG 29 0.00% 
PTCA 683 0.90% 
Rehabilitation 184 0.20% 
Community CPR 297 0.40% 
Hospital CPR 51 0.10% 
PTCA (NSTEMI) 774 1.00% 
Clopidogrel 69 0.10% 
Unstable angina† 2,102 (1,968 to 2,195) 2.8% (2.6% to 2.9%) 
Aspirin 501 0.70% 
Aspirin & Heparin 7 0.00% 
ACE inhibitor 80 0.10% 
Beta blockers 71 0.10% 
Spironolactone 212 0.30% 
IIb/IIIa 14 0.00% 
CABG 143 0.20% 
PTCA (STEMI) 806 1.10% 
Rehabilitation 28 0.00% 
Community CPR 28 0.00% 
Hospital CPR 1 0.00% 
Clopidogrel 212 0.30% 
Secondary prevention post 
myocardial infarction† 
1,478 (1,211 to 1,741) 2.0% (1.6% to 2.3%) 
Statins 380 0.50% 
Aspirin 272 0.40% 
Warfarin 47 0.10% 
ACE inhibitor 285 0.40% 
Beta blockers 272 0.40% 
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Rehabilitation 221 0.30% 
Secondary prevention post 
revascularisation† 
811 (681 to 984) 1.1% (0.9% to 1.3%) 
Statins 213 0.30% 
Aspirin 183 0.20% 
Warfarin 34 0.00% 
ACE inhibitor 147 0.20% 
Beta blockers 149 0.20% 
Rehabilitation 85 0.10% 
Angina in the community† 15,993 (15,515 to 16,499) 21.1% (20.5% to 21.8%) 
Statins 1,699 2.20% 
Aspirin 996 1.30% 
ACE inhibitor 7,356 9.70% 
Beta blockers 4,848 6.40% 
Spironolactone 610 0.80% 
CABG 484 0.60% 
Heart failure in patients 
requiring hospitalisation† 
3,441 (3,254 to 3,633) 4.5% (4.3% to 4.8%) 
Aspirin 666 0.90% 
ACE inhibitor 348 0.50% 
Beta blockers 1,473 1.90% 
Spironolactone 954 1.30% 
Heart failure in the community† 5,459 (4,844 to 6,130) 7.2% (6.4% to 8.1%) 
Aspirin 1,350 1.80% 
ACE inhibitor 623 0.80% 
Beta blockers 2,919 3.90% 
Spironolactone 567 0.70% 
Primary prevention therapies: 
Statins† 
2,996 (2,573 to 3,481) 4.0% (3.4% to 4.6%) 
Primary prevention therapies for 
high blood pressure† 
7,213 (5,828 to 8,628) 9.5% (7.7% to 11.4%) 
*95% uncertainty interval corresponds to 2.5th and 97.5th percentiles limits of uncertainty 
analysis for the 9 disease groups and total treatments. 
†Subtotals (in rows) for coronary heart disease patient groups. 
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blockers; 
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CABG, Coronary artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty; 
DPPs, deaths prevented or postponed.  
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What is already known this topic 
• Age-adjusted mortality of coronary heart disease (CHD) has declined since 1980 in many 
developed countries. 
• This mortality fall in Japan occurred in spite of recent increases in obesity and cholesterol, 
marking population aging, and Westernised dietary changes.  
• Those results have suggested that the decline of the age-adjusted CHD mortality may be 
explained by key factors other than obesity and total cholesterol in Japan.  
 
What this study adds 
• In Japan, the declining trend in CHD deaths was explained by policies in reduction of 
prevalence of smoking, elevated levels of systolic blood pressure, and by implementation of 
evidence-based treatment for CHD. 
• These successes have been partially offset by adverse increases in prevalence of diabetes and 
elevated levels of body mass index and cholesterol.  
• Japan should continue with their control policies for blood pressure and tabaco, and build an 
effective strategy to prevent diabetes and elevated levels of body mass index and cholesterol 
diabetes to prevent CHD deaths in the future. 
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